AU2002319422C1 - Aerosol formulations of delta8 tetrahydrocannabinol - Google Patents

Aerosol formulations of delta8 tetrahydrocannabinol Download PDF

Info

Publication number
AU2002319422C1
AU2002319422C1 AU2002319422A AU2002319422A AU2002319422C1 AU 2002319422 C1 AU2002319422 C1 AU 2002319422C1 AU 2002319422 A AU2002319422 A AU 2002319422A AU 2002319422 A AU2002319422 A AU 2002319422A AU 2002319422 C1 AU2002319422 C1 AU 2002319422C1
Authority
AU
Australia
Prior art keywords
aerosol formulation
condition
tetrahydrocannabinol
aerosol
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002319422A
Other languages
English (en)
Other versions
AU2002319422B2 (en
AU2002319422B8 (en
AU2002319422A1 (en
Inventor
Alan Langford
Austen John Woolfe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Norton Healthcare Ltd
Original Assignee
Norton Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Norton Healthcare Ltd filed Critical Norton Healthcare Ltd
Publication of AU2002319422B8 publication Critical patent/AU2002319422B8/en
Publication of AU2002319422A1 publication Critical patent/AU2002319422A1/en
Publication of AU2002319422B2 publication Critical patent/AU2002319422B2/en
Application granted granted Critical
Publication of AU2002319422C1 publication Critical patent/AU2002319422C1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
AU2002319422A 2001-07-10 2002-07-10 Aerosol formulations of delta8 tetrahydrocannabinol Ceased AU2002319422C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30502101P 2001-07-10 2001-07-10
US60/305,021 2001-07-10
PCT/GB2002/003161 WO2003006010A1 (en) 2001-07-10 2002-07-10 Aerosol formulations of δ8 tetrahydrocannabinol

Publications (4)

Publication Number Publication Date
AU2002319422B8 AU2002319422B8 (en) 2003-01-29
AU2002319422A1 AU2002319422A1 (en) 2003-05-22
AU2002319422B2 AU2002319422B2 (en) 2007-10-18
AU2002319422C1 true AU2002319422C1 (en) 2008-05-01

Family

ID=23178964

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002319422A Ceased AU2002319422C1 (en) 2001-07-10 2002-07-10 Aerosol formulations of delta8 tetrahydrocannabinol

Country Status (7)

Country Link
US (1) US20050079136A1 (enExample)
EP (1) EP1404314A1 (enExample)
JP (1) JP2004521950A (enExample)
KR (1) KR20040032851A (enExample)
AU (1) AU2002319422C1 (enExample)
CA (1) CA2453389A1 (enExample)
WO (1) WO2003006010A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2298284A3 (en) * 2001-02-14 2013-12-18 GW Pharma Limited Mucoadhesive pharmaceutical formulations
US20040248970A1 (en) * 2003-04-10 2004-12-09 Webster G.R. Barrie CBD-delta8-THC composition
EP1855666A1 (en) * 2005-02-25 2007-11-21 Unimed Pharmaceuticals, Inc. Dronabinol compositions and methods of using same
US20070060639A1 (en) * 2005-09-09 2007-03-15 University Of Kentucky Compositions and methods for intranasal delivery of tricyclic cannabinoids
US8039509B2 (en) 2006-11-10 2011-10-18 Johnson Matthey Public Limited Company Composition comprising (−)-Δ9-trans-tetrahydrocannabinol
US8980940B2 (en) 2006-11-10 2015-03-17 Johnson Matthey Public Limited Company Stable cannabinoid compositions and methods for making and storing them
US8222292B2 (en) 2007-08-06 2012-07-17 Insys Therapeutics, Inc. Liquid cannabinoid formulations
DE102007063210A1 (de) * 2007-12-20 2009-06-25 Eberhard-Karls-Universität Tübingen Universitätsklinikum Arzneimittel zur Behandlung von Phantomphänomenen
US10265293B2 (en) 2012-10-04 2019-04-23 Insys Development Company, Inc. Oral cannabinoid formulations
US9345771B2 (en) 2012-10-04 2016-05-24 Insys Development Company, Inc. Oral cannabinoid formulations
US11253472B2 (en) 2012-10-04 2022-02-22 Benuvia Therapeutics Llc Oral cannabinoid formulations
CA2925468A1 (en) 2013-09-26 2015-04-02 Ronald D. Sekura Topical treatments incorporating cannabis sp. derived botanical drug product
WO2015195711A2 (en) * 2014-06-16 2015-12-23 Shurtleff, James, Kevin Method and devices for manufacturing and delivering of aerosolized formulations
CA2952934A1 (en) 2014-06-26 2015-12-30 Island Breeze Systems Ca, Llc Mdi related products and methods of use
AU2015308546A1 (en) 2014-08-25 2017-04-13 Clk Consult V/ Carsten Leonhard Knudsen Device with compositions for delivery to the lungs, the oral mucosa and the brain
US9717683B1 (en) 2016-06-29 2017-08-01 Ep Pharma, Llc Low-temperature inhalation administration of cannabinoid entities
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
US10231948B2 (en) 2017-02-27 2019-03-19 Jason Ty Nguyen Metered dose inhaler compositions, systems, and methods
EP3745884A1 (en) 2018-01-31 2020-12-09 Canopy Holdings, Llc Hemp powder
US11040932B2 (en) 2018-10-10 2021-06-22 Treehouse Biotech, Inc. Synthesis of cannabigerol
US12496271B2 (en) 2019-02-22 2025-12-16 Benuvia Operations, Llc Oral cannabinoid formulations
US20200352191A1 (en) * 2019-05-06 2020-11-12 Karl Lonsbery Edible formulations and uses thereof
US11806645B1 (en) 2019-05-07 2023-11-07 Cannaceutical Extractions LLC Methods of producing CBD/THC oils
WO2021071967A1 (en) * 2019-10-09 2021-04-15 Island Breeze Systems Ca, Llc Compositions for pulmonary delivery of cannabinoids and associated methods and systems
US20220387352A1 (en) * 2020-07-29 2022-12-08 Medterra Pharma Llc Cannabinoid compositions and methods of using for the treatment of non-eosinophilic inflammation and inflammatory disorders
US20230131989A1 (en) * 2020-07-29 2023-04-27 Medterra Pharma Llc Cannabinoid compositions and methods of using for the treatment of non-eosinophilic inflammation and inflammatory disorders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999032107A1 (en) * 1997-12-19 1999-07-01 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Compositions comprising cannabinoids
WO2000024362A2 (en) * 1998-10-27 2000-05-04 Virginia Commonwealth University Δ9 tetrahydrocannabinol (δ9 thc) solution metered dose inhalers and methods of use
WO2001003668A1 (en) * 1999-07-08 2001-01-18 Her Majesty The Queen As Represented By The Minister Of National Defence Of Her Majesty's Canadian Government Pulmonary delivery of liposome-encapsulated cannabinoids

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4803978A (en) * 1985-08-09 1989-02-14 Johnson Iv John J Apparatus for actuating an inhaler
IL99468A (en) * 1991-09-12 1997-09-30 Yissum Res Dev Co (3s, 4s)-delta- 6-tetrahydrocannabinol- 7-oic acids and derivatives thereof, processes for their preparation and pharmaceutical compositions containing them
IL102082A (en) * 1992-06-02 1997-07-13 Yissum Res Dev Co Antiemetic composition containing a cannabinol derivative

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999032107A1 (en) * 1997-12-19 1999-07-01 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Compositions comprising cannabinoids
WO2000024362A2 (en) * 1998-10-27 2000-05-04 Virginia Commonwealth University Δ9 tetrahydrocannabinol (δ9 thc) solution metered dose inhalers and methods of use
WO2001003668A1 (en) * 1999-07-08 2001-01-18 Her Majesty The Queen As Represented By The Minister Of National Defence Of Her Majesty's Canadian Government Pulmonary delivery of liposome-encapsulated cannabinoids

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TASHKIN D P et al. Annual meeting American Lung Association in conjunction with Annual meeting American Thoracic Society and Annual meeting of Congress of Lung Association staff, XX, XX, vol. 119, no. 4, 13 may 1979, page 82 *

Also Published As

Publication number Publication date
EP1404314A1 (en) 2004-04-07
WO2003006010A1 (en) 2003-01-23
US20050079136A1 (en) 2005-04-14
JP2004521950A (ja) 2004-07-22
KR20040032851A (ko) 2004-04-17
AU2002319422B2 (en) 2007-10-18
AU2002319422B8 (en) 2003-01-29
CA2453389A1 (en) 2003-01-23

Similar Documents

Publication Publication Date Title
AU2002319422C1 (en) Aerosol formulations of delta8 tetrahydrocannabinol
AU2002319422A1 (en) Aerosol formulations of delta8 tetrahydrocannabinol
EP1124551B1 (en) Delta 9 tetrahydrocannabinol (delta 9 thc) solution metered dose inhalers and methods of use
EP2207528B1 (en) Pharmaceutical composition
US8367734B1 (en) Stable epinephrine suspension formulation with high inhalation delivery efficiency
GB2381450A (en) Administration of medicaments by vaporisation
JP2004500429A (ja) チオトロピウム及びロフレポニドを含む医薬用の組み合わせ
AU2002334126B2 (en) Pharmaceutical combinations comprising salmeterol and fluticasone proprionate for the treatment of asthma
CN116173025A (zh) 一种含格隆铵盐及茚达特罗盐的气雾剂药物组合物及其制备方法与应用
EP1274439A1 (en) Medical combination comprising salmeterol and budesonide
EP1278524A1 (en) Medical combinations comprising mometasone and salmeterol
EP4125869A1 (en) Cannabinoid compositions and aerosols
WO2001078738A1 (en) Medical compositions comprising (r,r)-formoterol and rofleponide
WO2007046113A2 (en) Novel pharmaceutical composition comprising alkaloid and process thereof
CN116196298A (zh) 一种含格隆铵盐的气雾剂药物组合物及其制备方法与应用
Prokopovich History of inhaler devices
WO2001078746A1 (en) Respiratory compositions
Mercier et al. Aerosolized THC for medical use: assessing the potential of vaping technology as a drug delivery device
WO2005123064A1 (en) Adrenergic complement inhaler comprising compounds such as ascorbates tocopherols or polycaboxylic acid chelators

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 21, NO 41, PAGE(S) 4753 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAME NORTON HEALTHCARE LIMITED, APPLICATION NUMBER 2002319422, UNDER INID (54), CORRECT THE TITLE TO READ AEROSOL FORMULATIONS OF DELTA8 TETRAHYDROCANNABINOL

FGA Letters patent sealed or granted (standard patent)
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 26 OCT 2007

MK14 Patent ceased section 143(a) (annual fees not paid) or expired